MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Sells Remaining MD Ownership Stake

 SRAX (NASDAQ: SRAX), an innovative fintech solutions provider that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire, today announced that it has sold its remaining interest in the SRAX MD asset. “Our SEQUIRE platform is rapidly growing and we are focused on the continued expansion of this business. We believe that selling the MD ownership stake at this time reinforces our goal of being 100% focused on providing our platform and services to public companies,” said Christopher Miglino, founder and CEO of SRAX. “This capital will be effective in helping us accelerate growth. This asset currently sits on our balance sheet with a zero basis, so this capital will go directly to improving our balance sheet. This transaction combined with moving BIGtoken to its own public company brings clarity to our mission going forward.”

To view the full press release, visit https://ibn.fm/Lp1v7

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Launch of New Branding for Upcoming Combination Clinical Trials

 Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the launch of new branding for its upcoming oncology clinical trials. The trials combine Genprex’s lead drug candidate, REQORSA(TM) (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso(R) (osimertinib), which received U.S. Food and Drug Administration (“FDA”) Fast Track Designation earlier this year, as well as the combination of REQORSA with Merck’s Keytruda(R) (pembrolizumab), for the treatment of non-small cell lung cancer (“NSCLC”). “We are enthusiastically preparing for our upcoming clinical trials and are excited to launch the adoption of this branding,” said Rodney Varner, president and chief executive officer of Genprex. “We believe the Acclaim brand communicates our passion for providing hope to NSCLC patients for important new treatment options in the fight against this devastating disease and aligns us with the clinical, medical and patient communities.”

To view the full press release, visit https://ibn.fm/Vw3ag

About Genprex Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s “Tagrisso(R)”) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information about the company, visit www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Wrap Technologies Inc. (NASDAQ: WRTC) Announces Q3 2020 Results, Appointment of Interim CEO and Chief Govt Affairs Officer

 Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, on Thursday announced results for its third quarter ended September 30, 2020. Among the Q3 highlights, the company reported a 275% growth in net sells, a gross margin of 32% and cash, cash equivalents and short-term investments of $45.1 million. In addition, the company’s board of directors named Tom Smith as its interim CEO, effective October 27, 2020. Marc Thomas stepped down from the CEO role and has been appointed to the newly created position of chief government affairs officer. “We are very excited for Tom to assume the additional responsibilities of Interim CEO as we continue to execute on our mission,” said Scot Cohen, executive chairman of the board. “Our goal is to have remote restraint become standard for every police officer worldwide. With 27 years of industry experience, Tom energizes the entire organization and knows the industry extremely well. Marc’s background, skills and passion will help drive change within government entities in this new role during these unprecedented times. As a White House Fellow with an exemplary military background and legislative experience, Marc’s ability to work with government leaders will enhance our position with police and security forces adoption of our technology and training which de-escalates conflict.”

To view the full press releases, visit https://ibn.fm/fiIoN and https://ibn.fm/fBIM8

About Wrap Technologies Inc.

Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, LaGrange, St. Cloud and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in BioWorld Article

 VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.” The publication discusses the merging of Affamed Therapeutics Ltd., an emerging biopharmaceutical company focused on opthamology markets in Greater China and funded by the large global venture capital firm, CBC Group, and EverInsight Therapeutics Inc., a biopharmaceutical company focused on central nervous system disorders and also funded by CBC Group. EverInsight and VistaGen entered into an exclusive development and commercialization agreement for VistaGen’s PH94B neuroactive nasal spray, a Phase 3-entering drug candidate for treatment of social anxiety disorder, earlier this year (https://ibn.fm/W6BOk). Under that agreement, VistaGen received a non-dilutive upfront payment of $5 million and, if Phase 3 development is successful, is eligible for up to $172 million in development and commercial milestone payment, plus royalties on commercial sales. According to the article, Affamed aims to bring in late-stage assets for China and other Asian markets focused on central nervous system and ophthalmology. As a result of the merger, VistaGen will work closely with the combined Affamed/EverInsight team on Phase 3 development and commercialization of PH94B in Greater China, South Korea and Southeast Asia. As noted in the article regarding the Affamed/EverInsight merger: “’In addition to bringing together complementary businesses, the combination strengthens the combined company’s global R&D capabilities,’ Affamed’s CEO Dayao Zhao told BioWorld. After the merger, Affamed now has a neurosteroid nasal spray, PH94B, which is moving into phase III development for social anxiety disorder with licensing rights from Vistagen Therapeutics Inc. in greater China, Korea and Southeast Asia.”

To view the full article, visit https://ibn.fm/ZkMnj

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN   

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Sustainable Green Team Ltd. (SGTM) Announces Audit Completion, Preparation for Uplisting, Receipt of New Order from 7-Eleven Stores

 Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, announced completion of its two-year 2018 and 2019 audit to commence the form-10 process to become fully reporting and for future uplisting. In addition, SGTM announced that its wholly owned subsidiary Mulch Manufacturing Inc. will be supplying quality mulch products and services to 7-Eleven stores throughout the Midwest U.S. and western New York, slated to commence in 2021. According to the update, the contract was received a week after the company closed an annual mulch supply contract with the City of Vero Beach, Florida. “Thanks to our VP of Sales Paul Stolly, we continue to secure major international chain accounts to start 2021 strong, commencing with 7-Eleven Inc.’s Midwest U.S. and western New York locations,” SGTM’s CEO and Director Tony Raynor said in the news release. “This allows us to build brand integrity and supply for future expansion as we progress.”

To view the full press releases, visit https://ibn.fm/VHu68 and https://ibn.fm/nQXIh

About Sustainable Green Team Ltd.

Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential, and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit http://ibn.fm/NYk36

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Announces Addition of BettermentRS, a Leading CBD Distributor

 The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER), a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, has added health and wellness, CBD-focused, direct-store delivery (DSD) distributor BettermentRS to its list of distributors. The move will enhance WTER’s convenience and grocery store CBD-sales growth. Based on recent research, sales of hemp-derived CBD products in the United States totaled $4.2 billion in 2019, which represents a 562% increase over the previous year. During the same period, sales of CBD products at c-stores and gas stores grew by more than 2,275%, topping out $122 million. The research also noted that CBD-infused drinks, tinctures and topicals are growth opportunities in the channel. In addition, the research reported that CBD drinks were valued at $52 million in c-store sales in 2019 and that CBD drinks are projected to remain popular among new consumers. “We are thrilled to partner with BettermentRS to represent A88CBD brand to some of the nation’s largest and fast-growing retail chains,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “BettermentRS will provide sales management, marketing, and logistics expertise to accelerate sales for our A88CBD line of products, particularly in the convenience store channel. CBD sales in the c-store channel are booming and represent a tremendous opportunity for our in-demand lifestyle brands. Sales of hemp-derived CBD products in the c-store channel were approximately $122 million in 2019 and grew roughly four times faster than the overall CDB market. BettermentRS will work closely with our sales team to introduce our brands to large accounts, including aforementioned, 7-Eleven and YesWay. . . .As a trusted national brand, we now offer a robust line of high-quality, lab-tested CBD topical and ingestible products. Our recent product announcements include gummies and CBD infused lemon-lime flavored water for our ingestibles line and deep relief cream and bath bombs for our topical line. With additional exciting new products and flavors coming soon and a growing base of strong channel partners, our A88CBD brand is well-positioned to capitalize on the increasing demand for CBD products across various trade channels.”

To view the full press release, visit https://ibn.fm/08967

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Talks Porcine Usage, Producing Synthetic Alternative

 AzurRx BioPharma (NASDAQ: AZRX), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, recently talked about its usage of porcine (pig) products in its production of pharmaceuticals and medicinals. Included in the discussion was a look at the disadvantages of such usage. AzurRx noted that pigs have been used for centuries in medical research and development; in fact, one study noted that pigs had been used in an estimated 20 medications and pharmaceuticals  including six for the pancreas, which are of particular interest for AZRX. There are downsides to such usage, the company noted, including supply chain, concentration and purity issues. Because of these issues, AzurRx is hoping  to develop synthetic replacement products. One of AZRX’s most promising treatments is MS1819, a lead product candidate being studied for the treatment of exocrine pancreatic insufficiency (“EPI”) associated with cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). The company is currently involved in several clinical trials for the drug, including two trial sites that were recently activated in Turkey. “We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial,” AzurRx chief medical officer Dr. James Pennington stated in the press release. “The recently reported interim data suggests promising results, and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the startup of this trial in a very efficient and effective manner, and we look forward to our continued work with them.”

To view the full press release, visit https://ibn.fm/KjZmz

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in New York, NY, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate

 Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of non-small cell lung cancer. The drug candidate was known previously by the laboratory designation GPX-001. The approval of the new name marks a critical branding milestone  for the company. Genprex’s REQORSA (pronounced “re-KORE-suh”) immunogene therapy features the company’s exclusive ONCOPREX(TM) nanoparticle delivery system that delivers cancer-fighting genes. The name will be resubmitted to the FDA for final review and approval after all required clinical trials are completed; that final approval is based on the FDA’s approval of the product candidate. The new name was based on FDA’s guidelines for the submission and evaluation of proprietary names. Genprex selected the name based on a comprehensive review of name candidates, including a study of healthcare practitioners across the country to guarantee accurate prescription and safety interpretation of the name. “We are very pleased to receive FDA’s conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer,” said Genprex president and CEO Rodney Varner in the press release. “This name approval also marks an important milestone in our overall branding strategy, giving us a unique, easily understood name people can associate with the Genprex brand and mission.”

To view the full press release, visit https://ibn.fm/O9uTf

About Genprex Inc. 

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html